{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T22:29:55Z","timestamp":1788474595409,"version":"build-2803163510"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Polish Ministry of Science and Higher Education","award":["N402 268836"],"award-info":[{"award-number":["N402 268836"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience Letters"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.neulet.2018.08.005","type":"journal-article","created":{"date-parts":[[2018,8,8]],"date-time":"2018-08-08T12:10:32Z","timestamp":1533730232000},"page":"152-155","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["In schizophrenia serum level of neurotrophin-3 (NT-3) is increased only if depressive symptoms are present"],"prefix":"10.1016","volume":"684","author":[{"given":"Ja\u015bmina","family":"Arabska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"\u0141ucka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8559-1078","authenticated-orcid":false,"given":"Dominik","family":"Strzelecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Wysoki\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neulet.2018.08.005_bib0005","doi-asserted-by":"crossref","first-page":"280","DOI":"10.4088\/JCP.08m04250yel","article-title":"Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study","volume":"71","author":"Bobes","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.neulet.2018.08.005_bib0010","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0920-9964(99)00205-4","article-title":"Depressive symptoms in stable chronic schizophrenia: prevalence and relationship to psychopathology and treatment","volume":"45","author":"Baynes","year":"2000","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neulet.2018.08.005_bib0015","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.neulet.2011.10.042","article-title":"Association of biomarkers and depressive symptoms in schizophrenia","volume":"505","author":"Noto","year":"2011","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neulet.2018.08.005_bib0020","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/wps.20440","article-title":"Schizophrenia and the neurodevelopmental continuum:evidence from genomics","volume":"16","author":"Owen","year":"2017","journal-title":"World Psychiatry"},{"key":"10.1016\/j.neulet.2018.08.005_bib0025","doi-asserted-by":"crossref","first-page":"8060","DOI":"10.1073\/pnas.87.20.8060","article-title":"Molecular cloning of a human gene that is a member of the nerve growth factor family","volume":"87","author":"Jones","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neulet.2018.08.005_bib0030","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.eurpsy.2004.06.020","article-title":"Neurotrophic factors and the pathophysiology of schizophrenic psychoses","volume":"19","author":"Durany","year":"2004","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.neulet.2018.08.005_bib0035","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0920-9964(00)00084-0","article-title":"Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses","volume":"52","author":"Durany","year":"2001","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neulet.2018.08.005_bib0040","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.euroneuro.2004.12.005","article-title":"The possible role of neurotrophins in the pathogenesis and therapy of schizophrenia","volume":"15","author":"Shoval","year":"2005","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neulet.2018.08.005_bib0045","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S0896-6273(02)01021-8","article-title":"Neurotrophin-3 is required for appropriate establishment of thalamocortical connections","volume":"36","author":"Ma","year":"2002","journal-title":"Neuron"},{"key":"10.1016\/j.neulet.2018.08.005_bib0050","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.jpsychires.2008.01.010","article-title":"Altered expression of neurotrophic factors in patients with major depression","volume":"42","author":"Otsuki","year":"2008","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.neulet.2018.08.005_bib0055","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3109\/08039488.2015.1087592","article-title":"Serum levels of brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3) in depressed patients with schizophrenia","volume":"70","author":"Wysokinski","year":"2016","journal-title":"Nord. J. Psychiatry"},{"key":"10.1016\/j.neulet.2018.08.005_bib0060","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0920-9964(90)90005-R","article-title":"A depression rating scale for schizophrenics","volume":"3","author":"Addington","year":"1990","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neulet.2018.08.005_bib0065","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.psychres.2014.01.039","article-title":"Depression in schizophrenia: the influence of the different dimensions of insight","volume":"216","author":"Misdrahi","year":"2014","journal-title":"Psychiatry Res."},{"issue":"5","key":"10.1016\/j.neulet.2018.08.005_bib0070","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/acps.12873","article-title":"The relationship between negative symptoms and depression in schizophrenia: a systematic review","volume":"137","author":"Krynicki","year":"2018","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.neulet.2018.08.005_bib0075","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.neulet.2007.01.002","article-title":"Serum neurotrophin-3 is increased during manic and depressive episodes in bipolar disorder","volume":"415","author":"Walz","year":"2007","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neulet.2018.08.005_bib0080","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.jpsychires.2009.11.020","article-title":"Increased neurotrophin-3 in drug-free subjects with bipolar disorder during manic and depressive episodes","volume":"44","author":"Fernandes","year":"2010","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.neulet.2018.08.005_bib0085","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.neulet.2008.04.027","article-title":"Decreased serum neurotrophin 3 in chronically medicated schizophrenic males","volume":"440","author":"Vargas","year":"2008","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neulet.2018.08.005_bib0090","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1080\/00207450802174589","article-title":"Does neurotropin-3 have a therapeutic implication in major depression?","volume":"118","author":"Pae","year":"2008","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.neulet.2018.08.005_bib0095","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1097\/00001756-200312020-00010","article-title":"Differential influence of BDNF and NT3 on the expression of calcium binding proteins and neuropeptide Y in vivo","volume":"14","author":"Agerman","year":"2003","journal-title":"Neuroreport"},{"key":"10.1016\/j.neulet.2018.08.005_bib0100","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1385\/JMN:14:1-2:027","article-title":"Expression of neurotrophins BDNF and NT-3, and their receptors in rat brain after administration of antipsychotic and psychotrophic agents","volume":"14","author":"Linden","year":"2000","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.neulet.2018.08.005_bib0105","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.neulet.2011.04.039","article-title":"Olanzapine plus fluoxetine treatment increases Nt-3 protein levels in the rat prefrontal cortex","volume":"497","author":"Agostinho","year":"2011","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neulet.2018.08.005_bib0110","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0006-8993(97)01525-4","article-title":"Permeability of the blood-brain barrier to neurotrophins","volume":"788","author":"Pan","year":"1998","journal-title":"Brain Res."},{"key":"10.1016\/j.neulet.2018.08.005_bib0115","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/S0028-3908(98)00141-5","article-title":"Transport of brain-derived neurotrophic factor across the blood-brain barrier","volume":"37","author":"Pan","year":"1998","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neulet.2018.08.005_bib0120","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1046\/j.1471-4159.1996.66010330.x","article-title":"Tissue distribution and immunocytochemical localization of neurotrophin-3 in the brain and peripheral tissues of rats","volume":"66","author":"Katoh-Semba","year":"1996","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neulet.2018.08.005_bib0125","doi-asserted-by":"crossref","first-page":"369","DOI":"10.7754\/Clin.Lab.2012.120404","article-title":"Serum neurotrophic factor levels in patients with type 2 diabetes mellitus: relationship to metabolic syndrome components","volume":"59","author":"Civelek","year":"2013","journal-title":"Clin. Lab."}],"container-title":["Neuroscience Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304394018305354?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304394018305354?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T04:46:09Z","timestamp":1536295569000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304394018305354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":25,"alternative-id":["S0304394018305354"],"URL":"https:\/\/doi.org\/10.1016\/j.neulet.2018.08.005","relation":{},"ISSN":["0304-3940"],"issn-type":[{"value":"0304-3940","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In schizophrenia serum level of neurotrophin-3 (NT-3) is increased only if depressive symptoms are present","name":"articletitle","label":"Article Title"},{"value":"Neuroscience Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neulet.2018.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}